publication date: Jul. 20, 2018

Conversation with The Cancer Letter Julia Beaver: SPARTAN and PROSPER showed MFS improvements greater than 20 months Julia Beaver

Julia Beaver

Director, Division of Oncology Products 1, FDA Center for Drug Evaluation and Research


The endpoint of metastasis-free survival is unlikely to be used in settings beyond non-metastatic castration-resistant prostate cancer, said Julia Beaver, director of Division of Oncology Products 1 at the FDA Center for Drug Evaluation and Research. 


Beaver spoke with Paul Goldberg, editor and publisher of The Cancer Letter.


Paul Goldberg:

A few days ago, FDA officials, you among them, wrote a perspective piece for NEJM about the new endpoint of metastasis-free survival. How is this endpoint different from other endpoints used by the agency? What does it see that other metrics of delay in progression don’t see?

Julia Beaver:

Metastasis-free survival is a time to event endpoint that measures the time from randomization to distant radiographic disease or death. Similar to other more commonly used endpoints, such as disease-free survival or recurrence-free survival, metastasis-free survival includes the transition from non-metastatic … Continue reading Julia Beaver: SPARTAN and PROSPER showed MFS improvements greater than 20 months

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.